Results 151 to 160 of about 5,281 (192)
Vaccine, 2017 Background In the elderly, traditional influenza inactivated vaccines are often only modestly immunogenic, owing to immunosenescence. Given that adjuvantation is a means of enhancing the immune response, the trivalent inactivated vaccine adjuvanted with ...
Joan Puig-barberà +2 more
exaly +2 more sources
Vaccine, 2010 We reviewed the safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents (aged 6 months-18 years) in an integrated analysis of all pediatric trials evaluating MF59-containing influenza vaccines completed to date (5 ...
Etienne Sokal +2 more
exaly +2 more sources
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
Expert Review of Vaccines, 2010 Approximately 70 years passed between the licensing of alum salts as vaccine adjuvants and that of MF59™ MF59, an oil-in-water emulsion, is currently licensed for use in the elderly as an adjuvant in seasonal influenza vaccines. Its mechanism of action is not fully understood, but enhancement of the interaction between the antigen and the dendritic ...
Hana El Sahly
exaly +2 more sources
Human Vaccines and Immunotherapeutics, 2015 Because of the age-related immune system decline, 2 potentiated influenza vaccines were specifically licensed for the elderly: Fluad®, an MF59-adjuvanted vaccine administered intramuscularly (IM-MF59), and Intanza 15mcg®, a non adjuvanted vaccine ...
Camilloni Barbara +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The mechanism of action of MF59 – An innately attractive adjuvant formulation
Vaccine, 2012MF59 is a safe and effective vaccine adjuvant which was originally approved to be included in a licensed influenza vaccine to be used in the elderly in Europe in 1997. The MF59 adjuvanted influenza vaccine (Fluad™) is now licensed in more than 20 countries worldwide and more than 85 million doses have been administered.
D T O’Hagan
exaly +3 more sources
Biodistribution and mechanisms of action of MF59 and MF59-like adjuvants
Journal of Controlled ReleaseRecently, adjuvants have received increasing attention as essential vaccine components. Nearly 100 years have passed since Gaston Roman introduced the concept of adjuvants in 1925, during which numerous preclinical and clinical studies related to vaccine adjuvants have been conducted.
Lili Cui, Lijun Bian
exaly +3 more sources
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
Vaccine, 1999Safety and immunogenicity of the influenza vaccine adjuvanted with MF59 (FLUAD) were compared to those of a non adjuvanted subunit vaccine in elderly subjects during three consecutive influenza seasons. Geometric mean titres and proportions of subjects with either a > or = four-fold increase in antibody titres or with an HI titre > or = 128 after ...
Audino Podda, B Fritzell
exaly +3 more sources
MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile
Expert Review of Vaccines, 2003 The need to enhance the immunogenicity of purified subunit antigens has prompted the development of several new adjuvants. However, many of these new molecules have demonstrated a reactogenicity profile that is not suitable for their inclusion in vaccines for human use.
Audino Podda
exaly +3 more sources
MF59 adjuvant: the best insurance against influenza strain diversity
Expert Review of Vaccines, 2011 MF59 is a well-established, safe and potent vaccine adjuvant that has been licensed for more than 13 years for use in an influenza vaccine focused on elderly subjects (Fluad®), Novartis, Cambridge, MA, USA). Recently, MF59 was shown to be safe in a seasonal influenza vaccine for young children and was able to increase vaccine efficacy from 43 to 89%. A
Rino Rappuoli +2 more
exaly +3 more sources